- Home
- BIIB vs BBDO Comparison
BIIB vs BBDO Comparison
Compare BIIB & BBDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BBDO
- Stock Information
- Founded
- BIIB 1978
- BBDO 1943
- Country
- BIIB United States
- BBDO Brazil
- Employees
- BIIB N/A
- BBDO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BBDO Major Banks
- Sector
- BIIB Health Care
- BBDO Finance
- Exchange
- BIIB Nasdaq
- BBDO Nasdaq
- Market Cap
- BIIB 24.2B
- BBDO 28.5B
- IPO Year
- BIIB 1991
- BBDO N/A
- Fundamental
- Price
- BIIB $175.74
- BBDO $3.05
- Analyst Decision
- BIIB Buy
- BBDO Strong Buy
- Analyst Count
- BIIB 23
- BBDO 4
- Target Price
- BIIB $176.48
- BBDO $2.55
- AVG Volume (30 Days)
- BIIB 2.0M
- BBDO 69.1K
- Earning Date
- BIIB 10-30-2025
- BBDO 10-29-2025
- Dividend Yield
- BIIB N/A
- BBDO 4.93%
- EPS Growth
- BIIB N/A
- BBDO 47.11
- EPS
- BIIB 10.97
- BBDO 0.38
- Revenue
- BIIB $10,065,900,000.00
- BBDO $16,507,289,161.00
- Revenue This Year
- BIIB $2.97
- BBDO $77.56
- Revenue Next Year
- BIIB N/A
- BBDO $7.49
- P/E Ratio
- BIIB $15.97
- BBDO $8.56
- Revenue Growth
- BIIB 4.77
- BBDO 16.68
- 52 Week Low
- BIIB $110.04
- BBDO $1.71
- 52 Week High
- BIIB $175.85
- BBDO $3.31
- Technical
- Relative Strength Index (RSI)
- BIIB 76.31
- BBDO 50.86
- Support Level
- BIIB $165.75
- BBDO $3.05
- Resistance Level
- BIIB $170.78
- BBDO $3.31
- Average True Range (ATR)
- BIIB 5.16
- BBDO 0.10
- MACD
- BIIB 1.34
- BBDO -0.01
- Stochastic Oscillator
- BIIB 98.74
- BBDO 29.27
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About BBDO Banco Bradesco Sa (each representing one Common Share)
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.